As part of our OMF End ME/CFS Project, this study will conduct a comprehensive, “Big Data,” analysis on severely ill ME/CFS patients with the goal of finding sensitive and distinctive molecular biomarker(s).
Very little research has been done in the bedbound. severely ill patients because they are hard to reach. By looking at the simple body fluids of the severely ill, we may discover distinctive biomarkers that have not been found in previous ME/CFS studies. By then testing these biomarkers in the less severely ill, we may discover an inexpensive and clinically useful diagnostic test. “Hopefully, the more severely ill will have a stronger signal of what’s going wrong,” said Dr. Davis, OMF Scientific Advisory Board Director. “As a result, we won’t need as many patients.”
“OMF has brought together a high caliber of scientists and laboratories with methods to approach this biomarker search and urgent research in depth,” said OMF Executive Director Linda Tannenbaum. “We will start with a few patients with our current funding. We urgently need more funding to increase the patient size and make this happen.
[button_color url=”http://www.openmedicinefoundation.org/donate-today-to-the-severely-ill-big-data-study/” content=”Donate to the Severely Ill Big Data Study” target=””] For more details on the OMF Severely Ill Big Data Study please read the study or the Question and Answer Article
Earlier in 2021, concerns were raised by people with ME about the REGAIN clinical trial and whether there was a risk to people suffering from post-viral symptoms, particularly post-exertional malaise. The REGAIN study aims to find out which of two treatments is better for helping people recover after being in hospital with Covid 19 –